INTRODUCTION
============

Reproduction success depends on the coordinated synthesis and release of several hormones from the hypothalamus--pituitary--gonadal axis. Mammalian gonadotropin-releasing hormone (known as GnRH 1) mediates brain control of reproductive activity and, as a major actor of gonadotrope axis, has received considerable attention. The neurohormone GnRH is a decapeptide produced by a small number of scattered hypothalamic neurons whose cell bodies are primarily located in the preoptic area and basal hypothalamus. GnRH neurons project to the median eminence and secrete GnRH in a pulsatile fashion into the hypophysial portal vessels through which GnRH is transported to the anterior pituitary gland. The release of GnRH by hypothalamic neurons is influenced by numerous external and internal factors acting through central nervous pathways. The pattern of pulsatile GnRH secretion thus varies widely in both males and females depending on the reproductive status. GnRH acts *via* its receptor specifically expressed in gonadotrope cells to stimulate both synthesis and exocytosis of the two gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH will in turn act on the gonads in a coordinated manner to initiate sexual maturation and regulate gonadal steroidogenesis and gametogenesis in both sexes. Gonadotrope hormones are complex endocrine signals constituted of non-covalently associated glycoprotein dimers. Each gonadotropin is composed of an alpha glycoprotein subunit common to LH, FSH, thyrotropin (TSH) and placental choriogonadotropin (for a few species) and a unique beta subunit.

The GnRH pulsatile pattern is critical for appropriate regulation of LH and FSH synthesis and secretion. Indeed, intermittent stimulation *in vivo* or *in vitro* that mimics the physiological pulsatile release of GnRH efficiently stimulates the secretion of gonadotropins. In contrast, a continuous pattern leads to desensitization of gonadotrope cells and this has been exploited by clinicians to suppress gonadotropin secretion ([@B19]). Furthermore, pulsatility of GnRH varies throughout the ovarian cycle and accounts for the differential secretion of LH and FSH. At mid-cycle, during proestrus, an abrupt and massive increase in GnRH pulsatility is responsible for gonadotropin surge and ovulation. Only little is known about the signaling mechanisms by which the pituitary gonadotrope cells decode GnRH pulse pattern. The aim of this article is to review the current knowledge on GnRH receptor (GnRH-R) coupling to the cyclic AMP (cAMP) signaling pathway in order to highlight its potential role in decoding high GnRH pulsatility.

COUPLING OF THE GnRH RECEPTOR TO THE cAMP SIGNALING PATHWAY
===========================================================

GnRH binds to a receptor belonging to the G protein-coupled receptor (GPCR) family with seven transmembrane domains connected by extracellular and intracellular loops. Agonist binding is mainly associated with a rapid Gq/11-mediated increase in phospholipase Cβ (PLCβ) activity, which will in turn initiate a wide array of signaling events. Hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) results in the formation of diacylglycerol (DAG) and inositol trisphosphate (IP3). Rapid formation of IP3 induces calcium release from intracellular stores and, together with GnRH-stimulated calcium influx, accounts for calcium oscillations that trigger gonadotropin exocytosis. Elevation of calcium also activates the nitric oxide synthase (NOS) cascade (NOS1/NO/soluble guanylate cyclase), resulting in a rapid increase of cyclic GMP (cGMP) levels ([@B30]; [@B24]). GnRH-induced DAG formation activates protein kinase C (PKC) isoforms belonging to the three known families of PKC (conventional, novel, and atypical), which mediate notably activation of mitogen-activated protein kinases (MAPK) cascades. PKC and MAPK signaling are crucial for the regulation of gonadotropin subunit gene expression ([@B36]). Following a short time lag, GnRH also activates phospholipase D (PLD) and phospholipase A2 (PLA2). PKC favors the coupling of GnRH-R to PLD leading to a sustained second wave of DAG that may contribute to maintain PKC activation during prolonged stimulation by GnRH ([@B42]). GnRH-mediated PLA2 activation generates arachidonic acid and its lipoxygenase products that have been implicated in GnRH-induced gonadotropin synthesis and release ([@B28]). The GnRH-R thus activates a wide array of signaling entities to regulate gonadotropin synthesis and release.

It has been clearly established that the cAMP/protein kinase A (PKA) pathway is essential for gonadotrope function. Indeed, cAMP analogs mimic most of the effects of GnRH as they enhance the release of newly synthesized LH and the expression of several key genes including those encoding LHβ and α subunits as well as GnRH-R and NOS1 ([@B35]; [@B11]; [@B17]). However, the ability of GnRH to induce cAMP production in gonadotrope cells as well as the involvement of cAMP in GnRH action has long remained debated. Early observation of [@B5] showed that a prolonged exposure (3 h) of rat hemipituitaries to GnRH stimulates cAMP accumulation and this observation was confirmed soon after by others ([@B29]). Since then, studies performed on dispersed rat pituitary cell cultures did not evidence any cAMP production or stimulation of adenylyl-cyclase (AC) activity in response to GnRH ([@B37]; [@B7]). In 1989, the pituitary AC-activating polypeptide (PACAP) was discovered based on its ability to strongly activate AC in rat pituitary cells ([@B26]). This probably contributed to lower the interest paid to GnRH-R signaling through the cAMP pathway. Furthermore, no GnRH-induced cAMP production could be substantiated on the first gonadotrope cell line that was established in the same period of time, the αT3-1 cell line ([@B16]). Accordingly, using photolabeling experiments, [@B14] argued for the exclusive coupling of GnRH-R to Gαq/11 in αT3-1 cells. Up to the early 2000s, the coupling of GnRH-R to the cAMP pathway in gonadotrope cells thus remained elusive. The ability of the mammalian GnRH-R to stimulate the cAMP pathway was however reported in several heterologous systems such as GH~3~, COS-7, or HeLa cells ([@B1]; [@B21]; [@B32]), thus reinforcing the interest for such coupling. The key to moving forward was the development of novel models and technologies. The ability of GnRH to induce cAMP accumulation in gonadotrope cells was demonstrated by two different groups including ours ([@B23]; [@B20]) using the gonadotrope cell line LβT2, which is more fully differentiated than the αT3-1 cell line. cAMP accumulation was evidenced by biochemical and enzyme-linked immunosorbent assays (ELISAs) and was specifically induced by GnRH-R activation as shown by competition with a GnRH antagonist. Further analysis revealed that different mechanisms contribute to GnRH-R-induced cAMP accumulation. Indeed, based on photolabeling experiments and on cell-permeable peptides that uncouple the receptor from Gαs, it was shown that GnRH-R activates cAMP production *via* Gs recruitment ([@B23]). Additionally, we demonstrated, using selective pharmacological inhibitors as well as dominant negative mutants of PKC isoforms, that novel PKCδ and ε mediate GnRH-R activation of the cAMP pathway ([@B20]). In both studies, GnRH-induced increase in cAMP levels exhibited atypical features. Indeed, GnRH-induced maximal accumulation of cAMP levels was observed only after a lag of time of approximately 30 min and was delayed as compared to response to PACAP ([@B20]) or to the beta-adrenergic receptor agonist, isoproterenol (J. Cohen-Tannoudji, personal communication). Furthermore, maximal cAMP accumulation was weaker and this may explain why GnRH-R coupling to this signaling pathway has long remained controversial. This prompted us to reevaluate the coupling of GnRH-R to the cAMP signaling pathway in αT3-1 cells using a recently developed technology. As reported previously by [@B16], we did not detect any significant increase in cAMP levels by ELISAs when cells were challenged with a GnRH agonist in contrast to response to PACAP or forskolin stimulation. We then took advantage of a sensitive technology based on the use of a cAMP biosensor (pGloSensor^TM^-22F cAMP Plasmid). αT3-1 cells were transfected with a plasmid encoding an engineered cAMP sensitive luciferase, which becomes active upon cAMP binding. Transfected cells were challenged with a GnRH agonist and the luminescence intensity was measured in real time in living cells. This strategy allowed us to demonstrate for the first time that GnRH-R couples to the cAMP pathway in αT3-1 cells ([@B2]). Indeed, GnRH dose-dependently increased luciferase activity reflecting cAMP production with an EC~50~ in the range of 1 nM and the increase was significantly inhibited by co-incubation with the GnRH antagonist, antide. Once the ability of GnRH to stimulate cAMP production was established in both gonadotrope cell lines, our efforts turned toward trying to understand whether this could also occurred in native gonadotrope cells. A massive pituitary cAMP level increase has been reported long ago to occur during the proestrus afternoon of the rat estrus cycle, coincidently with the GnRH preovulatory surge ([@B18]). However, despite such temporal coincidence, the precise contribution of GnRH has never been elucidated. We reevaluated this contribution *in vivo* by administrating a potent GnRH antagonist, the ganirelix, to females at the evening of the diestrus II ([@B12]). The marked decrease in pituitary cAMP levels provided evidence for a predominant role of GnRH in mediating the proestrus-specific rise of cAMP (**Figure [1](#F1){ref-type="fig"}**).

![**Profiles of serum LH and pituitary cAMP and NOS1 levels during the proestrus and following administration of a GnRH antagonist.** **(A)** Serum LH, pituitary cAMP, and pituitary NOS1 levels were determined by radioimmunoassay, ELISA, and western blot analysis, respectively. **(B)** Effect of an *in vivo* treatment with the GnRH antagonist, antarelix.^a^*P* \<0.05 and ^b^*P* \<0.01 compared with proestrus, \*\**P* \<0.01 compared with diestrus II. Modified from [@B18], [@B24], and [@B12].](fendo-03-00107-g001){#F1}

THE ATYPICAL STRUCTURE OF GnRH RECEPTOR IS ASSOCIATED WITH RESISTANCE TO RAPID DESENSITIZATION
==============================================================================================

All mammalian pituitary GnRH-R (named type I GnRH-R) exhibit a striking structural feature, which is the lack of a cytoplasmic carboxyl-terminal tail. This carboxyl-terminal tail is present in all other GPCR including GnRH-R from non-mammalian vertebrates and is a target for kinases such as GRK (GPCR kinase). GRK-mediated phosphorylation promotes the binding of β-arrestins, which not only uncouple receptors from G proteins resulting in desensitization but also target many GPCR for internalization in clathrin-coated vesicles ([@B9]). Given the unique absence of cytoplasmic carboxyl-terminal tail, the initial rate of inositol phosphate accumulation is linear upon 10 min of GnRH stimulation showing that GnRH-R is resistance to rapid desensitization ([@B8]). Accordingly, mammalian GnRH-R is not phosphorylated upon agonist stimulation and does not recruit β-arrestins, in contrast to non-mammalian GnRH-R ([@B39]; [@B25]). Extensive analysis of GnRH-R internalization has been performed using biochemical approaches and fluorescent or radiolabeled GnRH in gonadotrope and heterologous cells. These studies indicated that mammalian GnRH-R is poorly internalized as compared to non-mammalian GnRH-R and that addition of a functional intracellular carboxyl-terminal tail to the receptor significantly increased internalization rates and rapid desensitization. Whereas these studies were rather measuring ligand internalization, investigations conducted by Millar's group, using an epitope-tagged receptor allowed to trace the receptor itself. These studies established that GnRH-R exhibits a low level of constitutive internalization and does not undergo rapid agonist-dependent internalization as compared to non-mammalian GnRH or the TSH-releasing hormone receptors ([@B33]). The refractory state of gonadotrope cells under a sustained GnRH challenge is thus believed to occur through desensitization mechanism affecting downstream signaling entities such as Gαq/11, PKC isoforms, or IP3 receptors ([@B40]; [@B22]) rather than the receptor itself. Consequently, mammalian GnRH-R has the unique property amongst GPCR to face prolonged activation by its ligand.

MECHANISMS CONTRIBUTING TO GnRH-R COUPLING TO THE cAMP PATHWAY
==============================================================

One intriguing property of GnRH-R coupling to the cAMP pathway in LβT2 cells is that it appears to be dependent on GnRH stimulation pattern. We, indeed, observed that an intermittent stimulation of cells with GnRH, known to stimulate calcium release or MAPK activation, was ineffective in inducing cAMP accumulation ([@B20]). Levels of cAMP were significantly increased only under sustained stimulation of GnRH-R suggesting that this pathway may be preferentially recruited under high frequency of GnRH pulses, in agreement with the proestrus-specific elevation of pituitary cAMP levels during rat ovarian cycle ([@B18]; [@B12]). This shows that GnRH-R maintains cAMP pathway activation under stimulations inducing desensitization of most GPCR. This atypical feature was recently confirmed using fluorescence resonance energy transfer reporters in LβT2 cells in which high pulse frequency of GnRH desensitized DAG and calcium but not cAMP activation ([@B38]).

Only few genes regulated by GnRH through the cAMP/PKA signaling pathway have been identified so far. Among them are those encoding follistatin, Nur77, PACAP, and NOS1 ([@B41]; [@B15]; [@B13]; [@B27]; [@B12]). Interestingly, analysis of how GnRH regulates two of these genes has revealed that they are preferentially induced under high GnRH pulse frequency. Follistatin transcript and protein are increased by GnRH administered continuously or at fast frequency pulses either *in vivo* in rat or in a perifused pituitary cells ([@B3]) and not at slow GnRH pulse frequencies. Because follistatin binds to and neutralizes activin, stimulation of FSHβ by GnRH, which requires activin is blocked. This is believed to explain why expression of FSHβ is preferentially stimulated under low frequency of GnRH pulses. In rat anterior pituitary gland, NOS1 is expressed specifically in gonadotrope and folliculostellate cells. Our group has demonstrated from experiments performed *in vivo* in rats and *in vitro* that NOS1 expression is regulated by GnRH through the cAMP pathway ([@B10]; [@B24]). This was shown in particular by taking advantage of a cell-permeant PKA inhibitor (PKI) peptide delivery in primary cultures of rat pituitary cells ([@B12]). Interestingly, we observed that NOS1 is preferentially induced by prolonged GnRH treatment. Indeed, NOS1 expression remained at high levels for at least 48 h after treatment of rats with a long-lasting GnRH agonist, whereas, at the same time, LH and FSH secretion was desensitized. Accordingly, we demonstrated in perifused rat pituitary cells that NOS1 is not induced by GnRH delivered at a frequency of one pulse per hour, although this frequency is able to trigger a massive LH release. In contrast, NOS1 was maximally induced by a continuous GnRH stimulation, which suppressed gonadotropin release. Such a result is in agreement with *in vivo* data showing a marked increase of NOS1 expression at proestrus during the preovulatory GnRH surge, which is characterized by a very high GnRH pulse frequency ([@B24]; **Figure [1](#F1){ref-type="fig"}**). Interestingly, treatment with the GnRH antagonist ganirelix not only blocked the proestrus-specific cAMP increase (see above) but also significantly reduced the rise of NOS1 expression levels ([@B12]; **Figure [1](#F1){ref-type="fig"}**) further supporting the physiological relevance of GnRH-R coupling to the cAMP pathway. Altogether, experiments reported here, suggest that under conditions of high GnRH pulsatility, GnRH-R, which is atypically maintained at the cell surface, still interacts with its intracellular machinery and activates the cAMP/PKA pathway. This initiates the expression of a new set of target proteins among which are NOS1 and follistatin. The role of GnRH-dependent NOS1 induction at proestrus remains to be determined. The specific increase of NOS1 expression leads to a concomitant huge increase of pituitary cGMP levels at proestrus ([@B24]). cGMP may regulate some cyclic nucleotide-gated channels that we have characterized in pituitary gonadotrope cells (J. Cohen-Tannoudji, personal communication) and this is under investigation.

How is the preferential coupling of GnRH-R to the cAMP pathway selected? This question is still unresolved. GnRH-R is constitutively localized in low-density membrane microdomains such as rafts ([@B31]). Intense stimulation by GnRH may alter the signaling platform associated with GnRH-R in rafts and hence favor receptor coupling to the cAMP pathway. Another potential mechanism may be related to GPCR-interacting proteins (GIP) that interact through receptor intracellular domains to regulate signaling efficacy and specificity ([@B4]). The idea that GIP regulate GnRH-R signaling is suggested by the fact that introduction in αT3-1 cells of synthetic peptides corresponding to intracellular domains of mammalian GnRH-R increases GnRH-R coupling to the inositol phosphate pathway ([@B34]). We very recently identified a protein, the protein SET, as the first direct interacting partner of GnRH-R. Using cAMP and calcium biosensors in αT3-1 living cells combined with small interfering RNA directed against SET, we showed that SET significantly enhances GnRH-R coupling to the cAMP pathway. The mechanisms contributing to SET recruitment and the potential regulatory roles of SET on gonadotrope function are under current investigation.

CONCLUSION
==========

An important question in the field of reproductive endocrinology is to understand how the GnRH pulsatile pattern is decoded by pituitary gonadotrope cells. Due to its atypical structure and desensitization properties, GnRH-R and some of its signaling mechanisms are continuing to respond under massive GnRH stimulations. Such stimulations of gonadotrope cells by GnRH thus do not lead to general cell desensitization since some genes are induced in response to GnRH at high pulse frequencies. Variation in GnRH pulse profiles may lead to preferential activation of different signaling networks and there is now evidence that the cAMP/PKA pathway contributes to the decoding of high GnRH pulsatility. This emphasizes the unique feature of gonadotrope cells, which maintain part of their functional response under conditions of stimulation inducing desensitization of most GPCR. During the ovarian cycle, the GnRH preovulatory surge lasts much longer than the LH surge ([@B6]). Maintenance of some gonadotrope responsiveness while gonadotropins are no longer secreted may contribute to gonadotrope cell plasticity during the estrus cycle. Identifying the mechanisms directing the preferential coupling of GnRH-R to the cAMP pathway is an exciting challenge. Insight into GnRH-R interacting partners and into the dynamics of their interactions with the receptor will undoubtedly help to better understand the plasticity of gonadotrope cell signaling.
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